2026 Q2 -tulosraportti
13 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 077 | - | - | ||
| 6 631 | - | - | ||
| 5 149 | - | - | ||
| 2 077 | - | - | ||
| 6 983 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenI think it is petty of Nykode to issue 65 million new shares, and since this affects the market price. I don't remember exactly what the market price was before the issue, but it was probably around 4.5 kr/share. And with this issue, small shareholders get an offer to buy the share for 4.1 kr. Now the issue causes the price to go below 4.1 kroner. What advantage is there in buying the share at 4.1 kr, when the market price is around 4 kr. This is a completely legal practice, but it's the same as giving the finger to small shareholders who were already invested in the share before the issue, especially for those who have held the share for a long time, and eagerly awaited an upturn. Now, a biotechnology stock is a risky stock with a lot of uncertainty. The way they have chosen to carry out the issue makes the share more risky. Now the issue is necessary to raise money, but we small shareholders should have gotten the share for even cheaper money, at the price before the upturn.
A couple of clarifications on the math here: For those of us who owned shares before, it's actually good that the issue happened at a high price. 4.40 was among the year's highest levels; the price was at 2.50-3 as recently as this spring. The higher the price they raise at, the fewer new shares are needed for the same amount, and the less the dilution for us. To demand that small shareholders should have been able to subscribe at the price before the rise is, in practice, asking for greater self-dilution. And the money doesn't disappear even if the price falls. The 286 million is in the company regardless. So when the price is at approx 4 today, you are buying the company, including the fresh money, cheaper than the issue participants paid a week ago. Those who subscribed at 4.40 are in the red. You get the same company with the same full cash box at a lower price than what the best-informed actors voluntarily paid. That's not being fooled; it's coming out better than those who got to participate. What the money bought is also worth noting. The company is now financed past the Abili-T-interim data in 2027, and into 2029 with the tax money. The alternative was to risk a forced issue at a bottom price later, and that is the type of issue that truly crushes small shareholders. Raising at yearly high levels before you have to is the least painful variant found in biotech. One last thing: until now, every rise in NYKD has had a built-in brake; everyone knew an issue was coming sooner or later, and this time it came right after the peak. That brake is gone now. The next positive news, whether it's the tax decision, a partnership agreement, or Abili-T data, has no pending issue hanging over it. Then the price can actually go. Price drops right after issues are completely normal overhang and usually calm down within a few weeks. The values in the company are higher today than two weeks ago, now with the cash to prove it.
·3 päivää sittenMy thoughts are on the tax case. I wouldn't rule out that partners have been waiting for the outcome of this or that nykode itself has been holding back. +- a few hundred million makes for a good or bad hand when you're negotiating a deal, no matter which side of the table you're on. This will be exciting.
·3 päivää sittenWhat one wishes for: Well, a message about collaboration for VB10NEO. It's coming, now everyone has positioned themselves. 🧨………..🎇…………✨✨🚀
·3.9.My opinion: if one assumes that the price of 3-3.50 kr this summer was correct, then injected capital, peer-readout from Moderna, technical success with vb10.neo, granted patent and progress in the abili-T study should already have lifted the share well above today's price, even if one takes into account the increased number of shares. I am fully aware of the risk here, so I recommend nothing to anyone, but I myself believe that this gap will close over the next few months. Perhaps a licensing agreement is needed, but in that case, it should fundamentally change the price level.
Not to mention potentially around 1 kr per share extra from Skatteetaten, including interest, if the case ends positively. I'm really just sitting here waiting for the next positive news. Based on the communication from the company, active work is being done on partnering and collaboration around VB10.NEO. This of course doesn't mean that a deal is just around the corner, but if it does come, I believe today's share price level could quickly look quite different.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
13 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenI think it is petty of Nykode to issue 65 million new shares, and since this affects the market price. I don't remember exactly what the market price was before the issue, but it was probably around 4.5 kr/share. And with this issue, small shareholders get an offer to buy the share for 4.1 kr. Now the issue causes the price to go below 4.1 kroner. What advantage is there in buying the share at 4.1 kr, when the market price is around 4 kr. This is a completely legal practice, but it's the same as giving the finger to small shareholders who were already invested in the share before the issue, especially for those who have held the share for a long time, and eagerly awaited an upturn. Now, a biotechnology stock is a risky stock with a lot of uncertainty. The way they have chosen to carry out the issue makes the share more risky. Now the issue is necessary to raise money, but we small shareholders should have gotten the share for even cheaper money, at the price before the upturn.A couple of clarifications on the math here: For those of us who owned shares before, it's actually good that the issue happened at a high price. 4.40 was among the year's highest levels; the price was at 2.50-3 as recently as this spring. The higher the price they raise at, the fewer new shares are needed for the same amount, and the less the dilution for us. To demand that small shareholders should have been able to subscribe at the price before the rise is, in practice, asking for greater self-dilution. And the money doesn't disappear even if the price falls. The 286 million is in the company regardless. So when the price is at approx 4 today, you are buying the company, including the fresh money, cheaper than the issue participants paid a week ago. Those who subscribed at 4.40 are in the red. You get the same company with the same full cash box at a lower price than what the best-informed actors voluntarily paid. That's not being fooled; it's coming out better than those who got to participate. What the money bought is also worth noting. The company is now financed past the Abili-T-interim data in 2027, and into 2029 with the tax money. The alternative was to risk a forced issue at a bottom price later, and that is the type of issue that truly crushes small shareholders. Raising at yearly high levels before you have to is the least painful variant found in biotech. One last thing: until now, every rise in NYKD has had a built-in brake; everyone knew an issue was coming sooner or later, and this time it came right after the peak. That brake is gone now. The next positive news, whether it's the tax decision, a partnership agreement, or Abili-T data, has no pending issue hanging over it. Then the price can actually go. Price drops right after issues are completely normal overhang and usually calm down within a few weeks. The values in the company are higher today than two weeks ago, now with the cash to prove it.
- ·3 päivää sittenMy thoughts are on the tax case. I wouldn't rule out that partners have been waiting for the outcome of this or that nykode itself has been holding back. +- a few hundred million makes for a good or bad hand when you're negotiating a deal, no matter which side of the table you're on. This will be exciting.
- ·3 päivää sittenWhat one wishes for: Well, a message about collaboration for VB10NEO. It's coming, now everyone has positioned themselves. 🧨………..🎇…………✨✨🚀
- ·3.9.My opinion: if one assumes that the price of 3-3.50 kr this summer was correct, then injected capital, peer-readout from Moderna, technical success with vb10.neo, granted patent and progress in the abili-T study should already have lifted the share well above today's price, even if one takes into account the increased number of shares. I am fully aware of the risk here, so I recommend nothing to anyone, but I myself believe that this gap will close over the next few months. Perhaps a licensing agreement is needed, but in that case, it should fundamentally change the price level.Not to mention potentially around 1 kr per share extra from Skatteetaten, including interest, if the case ends positively. I'm really just sitting here waiting for the next positive news. Based on the communication from the company, active work is being done on partnering and collaboration around VB10.NEO. This of course doesn't mean that a deal is just around the corner, but if it does come, I believe today's share price level could quickly look quite different.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 077 | - | - | ||
| 6 631 | - | - | ||
| 5 149 | - | - | ||
| 2 077 | - | - | ||
| 6 983 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
13 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenI think it is petty of Nykode to issue 65 million new shares, and since this affects the market price. I don't remember exactly what the market price was before the issue, but it was probably around 4.5 kr/share. And with this issue, small shareholders get an offer to buy the share for 4.1 kr. Now the issue causes the price to go below 4.1 kroner. What advantage is there in buying the share at 4.1 kr, when the market price is around 4 kr. This is a completely legal practice, but it's the same as giving the finger to small shareholders who were already invested in the share before the issue, especially for those who have held the share for a long time, and eagerly awaited an upturn. Now, a biotechnology stock is a risky stock with a lot of uncertainty. The way they have chosen to carry out the issue makes the share more risky. Now the issue is necessary to raise money, but we small shareholders should have gotten the share for even cheaper money, at the price before the upturn.A couple of clarifications on the math here: For those of us who owned shares before, it's actually good that the issue happened at a high price. 4.40 was among the year's highest levels; the price was at 2.50-3 as recently as this spring. The higher the price they raise at, the fewer new shares are needed for the same amount, and the less the dilution for us. To demand that small shareholders should have been able to subscribe at the price before the rise is, in practice, asking for greater self-dilution. And the money doesn't disappear even if the price falls. The 286 million is in the company regardless. So when the price is at approx 4 today, you are buying the company, including the fresh money, cheaper than the issue participants paid a week ago. Those who subscribed at 4.40 are in the red. You get the same company with the same full cash box at a lower price than what the best-informed actors voluntarily paid. That's not being fooled; it's coming out better than those who got to participate. What the money bought is also worth noting. The company is now financed past the Abili-T-interim data in 2027, and into 2029 with the tax money. The alternative was to risk a forced issue at a bottom price later, and that is the type of issue that truly crushes small shareholders. Raising at yearly high levels before you have to is the least painful variant found in biotech. One last thing: until now, every rise in NYKD has had a built-in brake; everyone knew an issue was coming sooner or later, and this time it came right after the peak. That brake is gone now. The next positive news, whether it's the tax decision, a partnership agreement, or Abili-T data, has no pending issue hanging over it. Then the price can actually go. Price drops right after issues are completely normal overhang and usually calm down within a few weeks. The values in the company are higher today than two weeks ago, now with the cash to prove it.
- ·3 päivää sittenMy thoughts are on the tax case. I wouldn't rule out that partners have been waiting for the outcome of this or that nykode itself has been holding back. +- a few hundred million makes for a good or bad hand when you're negotiating a deal, no matter which side of the table you're on. This will be exciting.
- ·3 päivää sittenWhat one wishes for: Well, a message about collaboration for VB10NEO. It's coming, now everyone has positioned themselves. 🧨………..🎇…………✨✨🚀
- ·3.9.My opinion: if one assumes that the price of 3-3.50 kr this summer was correct, then injected capital, peer-readout from Moderna, technical success with vb10.neo, granted patent and progress in the abili-T study should already have lifted the share well above today's price, even if one takes into account the increased number of shares. I am fully aware of the risk here, so I recommend nothing to anyone, but I myself believe that this gap will close over the next few months. Perhaps a licensing agreement is needed, but in that case, it should fundamentally change the price level.Not to mention potentially around 1 kr per share extra from Skatteetaten, including interest, if the case ends positively. I'm really just sitting here waiting for the next positive news. Based on the communication from the company, active work is being done on partnering and collaboration around VB10.NEO. This of course doesn't mean that a deal is just around the corner, but if it does come, I believe today's share price level could quickly look quite different.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 077 | - | - | ||
| 6 631 | - | - | ||
| 5 149 | - | - | ||
| 2 077 | - | - | ||
| 6 983 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt